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1. Introduction  
The prevalence of diabetes mellitus, predominantly of type 2, has dramatically increased 
worldwide (Ritz et al., 2011). Diabetic nephropathy (DN) affects approximately one third of 
people with type 1 or type 2 diabetes mellitus (Reutens et al., 2011). In developed countries, 
the proportion of patients with diabetic kidney disease has stabilized despite increased use 
of glucose-lowering medications and renin-angiotensin-aldosterone system (RAAS)  
inhibitors (de Boer et al., 2011).  
DN typically develops after many years of diabetes, and is usually manifested clinically by 
gradually worsening albuminuria, followed by a decline in glomerular filtration rate, which 
over years or decades leads to end-stage renal disease. DN is characterized by specific renal 
morphological and functional alterations. Features of early diabetic renal changes are 
glomerular hyperfiltration, glomerular and renal hypertrophy, increased urinary albumin 
excretion, increased basement membrane thickness, and mesangial expansion with the 
accumulation of extracellular matrix proteins such as collagens, fibronectin, and laminin. 
Pathologic alterations of the tubulointerstitium such as fibrosis and tubular atrophy are also 
closely linked to the deterioration of renal function in patients with diabetes of both types 1 
and 2 (Wolf, 2000; Schrijvers et al., 2004). 
Despite the modern therapies like antidiabetic, antihypertensive, and antioxidant drugs 
available to treat DN, most of patients continue to show progressive renal damage. It 
suggests that the key pathogenic mechanisms involved in the induction and progression of 
DN are still remaining active and unmodified by the present therapies (Balakumar et al., 
2009). Many studies have attempted to elucidate the molecular signaling mechanisms that 
lead to DN so that effective therapies and preventive strategies might be developed. 
Through these efforts the general understanding of the pathogenic signaling factors that 
lead to progressive DN has expanded considerably during the past decade (Balakumar et 
al., 2009; Brosius et al., 2010). 
In recent years, extensive research has elucidated several pathways involved in the 
development and progression of diabetic kidney disease beyond the relevant role of high 
blood glucose (Schrijvers et al., 2004). Our knowledge of the pathophysiological processes in 
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DN has notably improved on a genetic and molecular level. Thus, the classic view of 
metabolic and hemodynamic alterations as the main causes of renal injury in diabetes has 
been transformed significantly, with clear evidence indicating that these traditional factors 
are only a partial aspect of a much more complex picture. One of the most important 
changes is related to the participation of immune-mediated inflammatory processes in the 
pathophysiology of diabetes mellitus and its complications (Navarro-Gonzalez & Mora-
Fernandez, 2008; Galkina & Ley, 2006; Shikata & Makino, 2001; Chow et al., 2004). 
Although DN is traditionally considered a non-immune disease, accumulating evidence 
now indicates that immunologic and inflammatory mechanisms play a significant role in its 
development and progression. DN also includes a variety of inflammatory responses 
induced by hyperglycemic conditions. Furthermore, microinflammation is a common major 
mechanism for the progression of DN. This process is mediated by elements of the immune 
system, including lymphocytes and monocytes/macrophages, as well as cytokines, growth 
factors, chemokines, adhesion molecules, enzymes, and nuclear factors. In this review we 
summarized cell processes, mediators and intracellular pathways participating in the 
immune and inflammatory response during the development of diabetic renal damage. 
2. Mechanisms of immune cell infiltration in the diabetic kidney 
2.1 Immune cells  
Yet, the molecular and cellular mechanisms of intrarenal inflammation in DN remain poorly 
characterized. Macrophages are the major inflammatory cells found in diabetic kidneys and 
their accumulation is a recognized feature in renal biopsies from diabetic patients (Xiao et 
al., 2009). In different experimental models of DN, renal macrophage accumulation 
correlates with the severity of glomerular and tubulointerstitial injury (Chow et al., 2004; 
Chow et al., 2005). However, it remains to be established whether macrophages are a major 
effector cell of diabetic renal damage, or merely recruited as a response to injury. Previous 
studies in diabetic animals reported the protective effect of mycophenolate or irradiation via 
reduction of renal macrophage infiltration (Wu et al., 2006). However, these treatments have 
additional effects on the kidney and immune system, and cannot be used for determining 
the long-term effects of macrophages on the progression of DN.  
Macrophages mediate immunopathology and tissue remodeling in both non-renal and renal 
diseases, and blocking macrophage recruitment prevents the progression of many types of 
kidney disease models (Ricardo et al., 2008). There are at least two subtypes of resident 
macrophages in tissues: the M1 macrophages, classically activated by Th1 stimuli, that 
express proinflammatory cytokines and enhances tissue inflammatory response; and the M2 
macrophages, alternatively activated by Th2 stimuli, that express antiinflammatory 
cytokines, and participate in the promotion of tissue repair, remodeling and vasculogenesis 
(Gordon, 2003). Obviously, modulating the macrophage phenotype is as important as 
reducing their overall number to prevent glomerular damage. The relative abundance of M1 
and M2 macrophages in the injured kidney changes dynamically by recruitment of 
polarized monocytes or through the effects of local cytokines on macrophages. Different 
chemokines are able to recruit circulating monocytes to extravascular compartments such as 
the glomerulus. Classically activated M1 macrophages represent one end of the spectrum as 
they produce upon stimulation high amounts of reactive oxygen species (ROS), and 
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proinflammatory cytokines, such as interleukins (ILs), tumor necrosis factor (TNF-ǂ), and 
interferon-Ǆ (IFN-Ǆ), all of which exacerbate inflammation and tissue injury in vivo 
(Mantovani et al., 2004). Alternatively activated M2 macrophages represent the other end of 
the spectrum and they participate in the resolution of inflammation through the secretion of 
antiinflammatory factors such as IL-10 and transforming growth factor-ǃ (TGF-ǃ), as well as 
by inhibiting the production of proinflammatory cytokines, chemokines, and superoxide 
anion (Martinez et al., 2008; Ricardo et al., 2008). Recent studies demonstrated a reduction in 
the severity of glomerular inflammation with adoptive transfer of cytokine-programmed M2 
macrophages (Ricardo et al., 2008). Furthermore, the antiinflammatory effects of statins 
(Fujita et al., 2010) and the angiotensin II type 1 receptor blocker olmesartan (Aki et al., 2010) 
in experimental glomerulonephritis are mediated through downregulation of M1 
macrophage infiltration as well as augmentation of antiinflammatory M2 macrophages and 
cytokines. Based on this, strategies to control the dynamic balance of macrophage 
polarization could have therapeutic interests in DN, and future studies will determine the 
place of these novel approaches in diabetic patients.  
T lymphocytes are known to play a significant role in renal injury induced by non-immune 
insults including ischaemia or toxins (e.g. adriamycin) (Lim et al., 2010). In patients with 
type 1 diabetes, the presence of nephropathy and proteinuria has been associated with 
increased activated peripheral blood T cells and also infiltration of T cells into the kidney 
(Xiao et al., 2009; Moriya et al., 2004; Ichinose et al., 2007), thus suggesting that lymphocyte 
activation may play a role in early DN. Activated T cells can cause injury directly through 
cytotoxic effects and indirectly by recruiting and activating macrophages. In addition, 
kidney autoantigens may develop during chronic diabetic renal injury and, if this occurs, B 
cells could present these antigens to T cells to promote their activation. Furthermore, 
diabetic patients have increased levels of serum immunoglobulins, which include antibodies 
(Abs) against proteins modified by glycoxidation or lipoxidation. These circulating Abs can 
form immune complexes (Atchley et al., 2002), which may deposit in glomeruli and promote 
activation of complement or macrophages via receptor interactions. Elements of the diabetic 
milieu can directly or indirectly activate T cells in diabetic kidneys. CD4+ T cells express the 
receptor for advanced glycation end products (AGEs) and can respond to AGEs by 
producing IFN-Ǆ, which could exacerbate inflammation in the diabetic kidney. In addition, 
hyperglycemia induces macrophage production of IL-12, which can also stimulate CD4 cell 
production of IFN-Ǆ (Wen et al., 2006; Lim et al., 2010). T lymphocyte-directed 
immunotherapies with anti-CD3 and anti-CD4 monoclonal Abs also induce disease 
remission in non-obese diabetic mice (Mehta et al., 2010). Some of them are currently in 
Phase III clinical trials for prevention of type 1 diabetes (Miller & St, 2011), although their 
renoprotective effects are not documented.  
2.2 Inflammatory mediators 
The infiltration of leukocytes into sites of inflammation is mediated by sequential binding to 
specific cell adhesion molecules and chemokine and cytokine release that together promote 
rolling, arrest, firm adhesion, transmigration, and activation (Hogg & Berlin, 1995). A large 
array of cell adhesion molecules, chemokines, and cytokines have been shown to be 
important in leukocyte accumulation and renal injury in models of non-diabetic and diabetic 
kidney damage, and some of these mediators are also found elevated in renal biopsies from 
diabetic patients (Navarro-Gonzalez & Mora-Fernandez, 2008; Galkina & Ley, 2006; Shikata 
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& Makino, 2001; Chow et al., 2004). The most representative members for each family are 
discussed below. 
2.2.1 Adhesion molecules: ICAM-1 
Intercellular adhesion molecule (ICAM)-1 is a 90-kD cell surface glycoprotein of the Ig 
superfamily involved in the firm attachment of leukocytes to endothelium (Staunton et al., 
1988), which interacts with lymphocyte function-associated antigen (LFA)-1 (CD11a/CD18) 
and Mac-1 (CD11b/CD18) that are present on most leukocytes. ICAM-1 expression is 
upregulated and associated with leukocyte infiltration and disease progression in 
experimental models of type 1 and type 2 DN (Sugimoto et al., 1997; Coimbra et al., 2000) 
and also in diabetic patients (Rubio-Guerra et al., 2009). ICAM-1 is induced by factors 
common to both types of diabetes, such as hyperglycemia, AGEs, hyperfiltration, and 
oxidative stress, but it can also be increased by additional elements such as hyperlipidemia, 
hyperinsulinemia, and elevated levels of circulating TNF-ǂ (Chow et al., 2006). Previous 
evidence from genetically deficient mice demonstrated that ICAM-1 is a critical mediator of 
macrophage accumulation in diabetic kidneys both in early and late stages of diabetes 
(Okada et al., 2003; Chow et al., 2005), while treatment with anti-ICAM-1 monoclonal Ab 
prevents mononuclear cell infiltration into diabetic glomeruli (Sugimoto et al., 1997). 
Furthermore, the reduced ICAM-1 overexpression is one of the renoprotective effecs of 
taurine treatment in streptozotocin-induced diabetic rats (Wang et al., 2008).  
2.2.2 Chemokines: MCP-1 
Monocyte chemotactic protein-1 (MCP-1) is a small cytokine belonging to the CC chemokine 
family that is also known as chemokine (C-C motif) ligand 2 (CCL2). MCP-1 recruits 
monocytes, T cells, macrophages and dendritic cells to sites of tissue injury, infection, and 
inflammation, and is gaining interest as a mediator of DN. MCP-1 is induced by high 
glucose concentrations, AGEs and cytokines in cultured renal cells (Chow et al., 2006), and 
its expression increases progressively in diabetic kidneys from different animal models. In 
diabetic patients, MCP-1 urinary levels correlate with albuminuria, therefore being 
considered a marker of renal function decline (Sayyed et al., 2011; Camilla et al., 2011). 
MCP-1 is a potent chemokine involved in the accumulation and function of macrophages 
(Chow et al., 2006), thus playing a role in the inflammatory phase of DN. Renal cells like 
podocytes and mesangial cells are also able to produce MCP-1 in response to metabolic 
mediators, such as high glucose, and AGEs, and also by activation of RAAS and TGF-ǃ 
(Yamagishi & Matsui, 2010). Renal cells are susceptible to paracrine and autocrine activation 
by MCP-1, through the interaction with CCR2, the main receptor of MCP-1 (Sayyed et al., 
2011; Camilla et al., 2011). In fact, MCP-1/CCR2 system is involved in podocyte 
cytoskeleton reorganization and motility, and also in mesangial expression of fibronectin 
and type IV collagen (Lee et al., 2009; Park et al., 2008). Diabetic mice with gene deficiency in 
MCP-1 are protected from glomerular macrophage infiltration, renal injury, and 
development of albuminuria (Chow et al., 2006).  
As upregulation of kidney MCP-1 is a feature of human diabetic renal injury associated with 
macrophage recruitment and disease progression, neutralizing MCP-1 activity should be 
viewed as an important therapeutic goal in the treatment of DN. Preclinical studies have 
demonstrated that blockade of MCP-1/CCR2 system with RO5234444, an orally active 
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small-molecule CCR2 antagonist, reduced glomerular macrophage content, 
glomerulosclerosis, and albuminuria in diabetic mice, and also improved glomerular filtration 
rate (Sayyed et al., 2011; Camilla et al., 2011). Furthermore, the renoprotective effect of several 
compounds, including pioglitazone (Hu et al., 2010), clarithromycin (Tone et al., 2011), and 
exenatide (Wu et al., 2011) has been related to the local reduction of MCP-1 activity within the 
kidney. Furthermore, the indazolic derivative bindarit (AF-2838) is a potent antiinflammatory 
agent that inhibits chemokine synthesis, particularly MCP-1. Phase II trials in rheumatoid 
arthritis and lupus nephritis have shown that bindarit significantly reduced urinary MCP-1 
and albumin excretion rate. A clinical trial aimed to reduce albuminuria and renal disease 
progression with bindarit added onto RAAS blockade therapy is ongoing in type 2 diabetic 
patients with micro- or macroalbuminuria (Cortinovis et al., 2008). 
2.2.3 Cytokines: IL-1, IL-6, and TNF-α  
There is growing support for the notion that circulating proinflammatory cytokines, such as 
ILs and TNF-ǂ, are strongly associated with the risk of developing diabetic complications 
(Shikata & Makino, 2001). ILs comprise a large group of cytokines secreted by leukocytes 
and other body cells that can be classified as proinflammatory and antiinflammatory. In 
particular, the proinflammatory IL-1 increases the expression of chemotactic factors and 
adhesion molecules, enhances vascular endothelial permeability, and stimulates the 
proliferation of mesangial cells and matrix synthesis (Rivero et al., 2009). Renal IL-1 
expression is found increased in diabetic animals and correlates with albuminuria and 
macrophage content (Hasegawa et al., 1991; Sassy-Prigent et al., 2000; Navarro et al., 2006). 
Specific blockade of IL-1 activity by the IL-1 receptor antagonist anakinra reduced the 
release of inflammatory cytokines and chemokines in pancreatic islet from diabetic rats, and 
also decreased hyperglycemia and improved insulin sensitivity (Ehses et al., 2009). In type 2 
diabetic patients, anakinra improved glycemia and beta-cell secretory function and reduced 
markers of systemic inflammation (Larsen et al., 2007). Further studies are needed to 
demonstrate the biological effects of this compound on diabetic kidneys. 
IL-6 is a pleiotropic cytokine secreted by renal cells in response to a diabetic milieu (Min et al., 
2009; Tang et al., 2010a) that stimulates mesangial cell proliferation, affects extracellular matrix 
dynamics in renal cells, and enhances endothelial permeability (Navarro-Gonzalez & Mora-
Fernandez, 2008; Galkina & Ley, 2006; Shikata & Makino, 2001; Chow et al., 2004). Serum IL-6 
levels are significantly increased in patients with type 2 DN compared to levels observed in 
diabetic patients without nephropathy (Navarro-Gonzalez & Mora-Fernandez, 2008; Galkina 
& Ley, 2006; Dalla et al., 2005), and studies in renal biopsies revealed a significant association 
between the severity of diabetic glomerulopathy and the expression levels of IL-6 in 
glomerular cells (Suzuki et al., 1995), thus suggesting a role for IL-6 in the pathogenesis of DN. 
There are no direct data of treatment against elevated IL-6 levels in DN, however there are 
indirect evidences. In a recent study in patients with incipient and established DN, the 
treatment with pentoxyfylline, a methylxanthine derivate and nonselective phosphodiesterase 
inhibitor, caused a decrease in the urinary albumin excretion, and this renoprotective effect 
was attributable in part to reduced levels of IL-6 among other proinflammatory mediators 
(Hasegawa et al., 1991; Sassy-Prigent et al., 2000; Navarro et al., 2006).  
TNF-ǂ is a pleiotropic cytokine produced mainly by monocytes/macrophages that is 
involved in systemic inflammation (Sugimoto et al., 1999). TNF-ǂ exerts cytotoxic effects on 
renal cells (McCarthy et al., 1998; Min et al., 2009), and it has been shown to participate in 
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renal damage development in experimental models of renal disease including lupus 
nephritis, glomerulonephritis, nephropathy, hypertension, and diabetes (McCarthy et al., 
1998; Elmarakby & Sullivan, 2010). A role for TNF-ǂ in DN is supported by the finding that 
urinary albumin excretion significantly correlates with renal TNF-ǂ levels and urinary TNF-
ǂ excretion in streptozotocin-induced diabetic rats (Navarro et al., 2005). TNF-ǂ also 
contributes to sodium retention and renal hypertrophy, which are early characteristic signs 
of streptozotocin-induced DN (DiPetrillo et al., 2003). Renal TNF-ǂ expression, particularly 
in the glomerulus and tubulointerestitium, is increased in streptozotocin diabetic rat 
kidneys, and serum TNF-ǂ is increased in type 2 diabetic patients (Navarro et al., 2005). 
Therefore, TNF-ǂ plays an important role in the incidence and progression of DN and renal 
TNF-ǂ levels correlate with markers of DN. 
Strategies to inhibit TNF-ǂ have been successfully used in experimental diabetes. DiPetrillo 
et al. (DiPetrillo et al., 2003) reported that treatment of diabetic rats with the anti-TNF-ǂ 
agent TNFR:Fc, a soluble TNF-ǂ receptor fusion protein, reduced urinary TNF-ǂ excretion 
and prevented sodium retention and renal hypertrophy. Similarly, TNF-ǂ inhibition with 
infliximab, a chimeric monoclonal Ab directed against TNF-ǂ, significantly reduced both 
albuminuria and urinary TNF-ǂ in streptozotocin-induced diabetic rats (Moriwaki et al., 
2007). Unfortunately, no other parameters such as structural changes or hemodynamics 
were studied. A recent retrospective study evaluated the effects of anti–TNF-ǂ agents on 
control of type 2 diabetes in patients with rheumatoid arthritis and Crohn's disease. Anti-
TNF treatment improved glucose tolerance and control, although future prospective studies 
are needed to solidify these results (Gupta-Ganguli et al., 2011). 
3. Molecules involved in the progression of diabetic renal disease 
3.1 Growth factors: TGF-β, CTGF, and VEGF 
Hyperglycemia stimulates resident and non-resident renal cells to produce cytokines and 
growth factors that contribute to the development of renal injury. In particular, the 
expression of the profibrotic factor TGF-ǃ is increased in both type 1 and type 2 diabetes 
(Cortinovis et al., 2008). Other growth factors are also implicated, including vascular 
endothelial growth factor (VEGF), connective tissue growth factor (CTGF), among others 
acting through several intracellular signaling pathways comprising protein kinases and 
transcription factors (Goh et al., 2008). Recently, specific Abs against different growth factors 
that might be useful for the treatment of chronic nephropathies, including DN, have been 
developed (Cortinovis et al., 2008). 
3.1.1 TGF-β  
TGF-ǃ is a well-known profibrogenic factor which controls synthesis and degradation of 
extracellular matrix proteins by stimulating transcription of extracellular matrix genes in 
renal cells and reducing collagenase production, eventually inhibiting matrix turnover. 
Furthermore TGF-ǃ is involved in tubuloglomerular sclerosis and podocyte apoptosis in 
diabetes. TGF-ǃ gene and protein levels are significantly increased in glomeruli and 
tubulointerstitium of type 1 and 2 diabetic patients and animals (Yamagishi & Matsui, 2010; 
Goh et al., 2008). Factors that regulate TGF-ǃ expression in renal cells include 
hyperglycemia, AGEs, endothelin, lipids and products of oxidative stress. TGF-ǃ is also 
modulated by the RAAS (Goh et al., 2008). In fact, angiotensin II stimulates TGF-ǃ and its 
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receptors in the kidney by various mechanisms, and angiotensin converting enzyme (ACE) 
inhibition reduces serum and urinary levels of TGF-ǃ (Wolf, 2006). In diabetic patients, 
treatment with the ACE inhibitor perindopril reduced the intrarenal TGF-ǃ expression 
and activity (Langham et al., 2006). Furthermore, the antifibrotic agent N-acetyl-seryl-
aspartyl-lysyl-proline, which reduced TGF-ǃ-induced extracellular matrix production and 
prevented renal fibrosis and albuminuria in diabetic db/db mice, conferred an additional 
renoprotective effect when combined with the angiotensin II receptor antagonist losartan 
(Sugaru et al., 2006).  
A range of novel compounds has been recently examined to inhibit TGF-ǃ and TGF-ǃ-
dependent pathways in diabetes. Several blocking Abs against TGF-ǃ effectively reduce 
mesangial matrix accumulation and glomerulosclerosis in diabetic mouse models (Ziyadeh 
et al., 2000; Goh et al., 2008), and particularly the TGF-AY1 Ab is in clinical development for 
the treatment of chronic kidney disease, with focus on DN (Cortinovis et al., 2008). In 
addition, the soluble human TGF-ǃ type II receptor (sT ǃ RII-Fc), a high-affinity TGF-ǃ1 
binding molecule, has been proposed as a potential new agent for the treatment of fibrosis 
and albuminuria in DN (Russo et al., 2007). 
A potential therapeutic approach is the use of micro RNA (miRNA)-based strategies. The 
miRNAs are short noncoding nucleotides that regulate target messenger RNAs at the post-
transcriptional level and are involved in many biological processes (Lorenzen et al., 2011). 
Recent studies have identified miRNA-mediated circuits controlling auto-upregulation of 
TGF-ǃ1 and amplification of TGF-ǃ1 signaling that accelerate chronic fibrotic kidney 
diseases including DN (Kato et al., 2011). In particular, miRNA-92c and miRNA-192 are 
induced in renal cells by high glucose and TGF-ǃ, and mediate cell apoptosis and 
extracellular matrix accumulation (Kato et al., 2011; Long et al., 2011). Renal expression of 
these miRNAs increased in type 1 and type 2 diabetic animals, and in vivo knockdown 
prevented progression of DN. Their widespread and distinct expression patterns under 
normal and disease states make miRNAs attractive molecular therapeutic targets for human 
diseases. In fact, different miRNA modulators (such as antagomirs and locked nucleic acid 
antimiRs) have been developed for specific targeting of miRNAs and respective 
downstream gene networks (Lorenzen et al., 2011). The therapeutic potential of miRNA-
based treatment in DN requires further study.  
3.1.2 CTGF 
Several reports have described an increased expression of CTGF in diabetic kidneys, that is 
therefore being considered a marker and a mediator of disease. Synthesis of CTGF is 
stimulated by TGF-ǃ, hyperglycemia and AGEs, as well as CTGF itself. CTGF induces 
mesangial cell hypertrophy and cytoskeletal disassembling, upregulates cell production of 
fibronectin and collagens, and is also involved in epithelial-to-mesenchymal transition of 
tubular cells (Twigg, 2010; Connolly et al., 2003).  
CTGF is also an important downstream mediator of the profibrotic activity of TGF-ǃ. But in 
contrast to TGF-ǃ, CTGF is not centrally involved in the modulation of inflammation or 
immune reactions (Goldschmeding et al., 2000) and thus this profibrotic factor may be a 
more attractive target for new renoprotective therapies. In fact, decreased CTGF expression 
in the kidney has been suggested as the mechanism involved in the inhibition of diabetic 
renal damage by different agents including the AGE inhibitors aminoguanidine (Twigg & 
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Cooper, 2004) and XLF-III-43 (Li et al., 2010), the aldosterone receptor blocker 
spironolactone (Han et al., 2006), and the flavonoid compound astilbin (Li et al., 2009). More 
specific therapies include FG-3019, a humanized monoclonal Ab that neutralizes the effects 
of CTGF in diabetic animals (Cortinovis et al., 2008). FG-3019 is currently under 
development for idiopathic pulmonary fibrosis, pancreatic cancer and diabetes. In an open-
label, dose-escalation Phase Ib trial in type 1 or 2 diabetic patients with incipient 
nephropathy, FG-3019 effectively decreased albuminuria (Adler et al., 2010), although 
further validation in a prospective, randomized, blinded study is required. 
3.1.3 VEGF 
VEGF is a potent inducer of vasopermeability and angiogenesis that plays a major 
pathophysiological role in DN, despite VEGF exhibiting protective roles in non-diabetic renal 
disease. Serum levels of VEGF correlate with albuminuria and increase with DN stage in 
patients with type 1 and 2 diabetes (Hovind et al., 2000). Several experimental model studies 
have demonstrated that VEGF may contribute to some of the hemodynamic changes in DN, 
including hyperfiltration and albuminuria. Expression of VEGF and its receptors are 
modulated by high glucose, endothelin 1, AGEs, angiotensin II, stretch and TGF-ǃ, and their 
renal expression is increased in diabetic kidneys (Chen & Ziyadeh, 2008; Cooper et al., 1999). 
Furthermore, VEGF is a trophic factor for glomerular endothelial cells, affects podocyte 
function, and is also involved in macrophage influx during early DN (Chen & Ziyadeh, 2008).  
Since VEGF levels are elevated in patients and animal models of DN, a number of studies 
have examined the effect of inhibition of VEGF receptor binding or activation. Antagonism 
of VEGF using a variety of different strategies has been reported to improve the outcome in 
experimental nephropathies of various origins, including DN. Neutralizing VEGF Abs 
ameliorate early and long-term renal changes in diabetic animals (De Vriese et al., 2001; 
Schrijvers et al., 2006), while treatment with the pan-VEGF receptor tyrosine kinase inhibitor 
SU5416 ameliorates diabetic albuminuria in mice (Sung et al., 2006). Several clinical studies 
have evaluated the beneficial effect of these anti-VEGF agents in the treatment of diabetic 
retinopathy, but more studies are needed to determine the viability of such strategy in 
diabetic renal disease. 
3.2 Oxidative stress 
Oxidative stress defined as an excessive production of ROS surpassing existing antioxidative 
defense mechanisms plays a critical role in the pathogenesis of diabetes, and more importantly 
in the development of diabetic complications, including DN. Free radicals are capable of 
disturb physiological cell function both directly, by damaging cellular macromolecules such as 
DNA, proteins, and lipids, and indirectly through the stimulation of multiple pathways, such 
as protein kinases, polyol and hexosamine pathways and AGEs formation. In addition, low 
antioxidant bioavailability promotes cellular oxidative stress leading to additional cellular 
damage (Forbes et al., 2008; Elmarakby & Sullivan, 2010; Noh & Ha, 2011). 
Overproduction of ROS in the diabetic milieu is both a direct consequence of hyperglycemia 
and an indirect consequence through AGEs or mediators of glucotoxicity such as cytokines 
and growth factors (Noh & Ha, 2011; Forbes et al., 2008). The effects of ROS in renal cells 
comprise mesangial cell proliferation, expression of growth factors, extracellular matrix 
accumulation, RAAS activation and induction of epithelial-mesenchymal transition (Noh & 
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Ha, 2011; Elmarakby & Sullivan, 2010). Among many pathways, nicotinamide adenosine 
dinucleotide phosphate (NADPH) oxidase and mitochondrial dysfunction have been 
recognized as two major sources of ROS generation in diabetic kidneys, and NADPH 
oxidase-derived ROS has been shown to facilitate renal mitochondrial superoxide 
production in hyperglycemia (Tojo et al., 2007).  
Inhibition of ROS production and their activity has been demonstrated to be effective in 
preventing the development and progression of experimental diabetes. Different approaches 
including oral administration of resveratrol (Palsamy & Subramanian, 2011)  and dietary 
antioxidant supplementation with N-acetylcysteine, vitamins C and E (Park et al., 2011) and 
curcuminoids (Sharma et al., 2006) have been shown to reduce oxidative stress and renal 
inflammation in diabetic animals. Clinical observations have also revealed a positive effect 
on oxidative stress in diabetic patients (Gupta et al., 2011). Alternative strategies based on 
upregulation of antioxidant proteins, such as superoxide dismutase, heme oxygenase-1, and 
catalase, have also been proven to diminish high glucose-induced ROS in cell cultures and 
animal models (Li et al., 2011). A recent study in diabetic animals reported the 
renoprotective effects of luteolin (Wang et al., 2011), a plant-derived flavonoid with 
antiinflammatory and antitumorigenic properties (Lopez-Lazaro, 2009). The improvement 
of renal function in luteolin treated animals was associated with changes in superoxide 
dismutase activity, malondialdehyde content and expression of heme oxygenase-1 
expression (Wang et al., 2011). New strategies targeting NF-E2-related factor 2, the 
transcription factor that controls antioxidant protein expression, mitochondrial dysfunction, 
and NADPH oxidase might provide a potential approach for the prevention and treatment 
of DN (Noh & Ha, 2011).  Presently, designing new antioxidant therapies focus on effective, 
cell compartment-specific agents that would improve renoprotection in combination with 
current therapies (Forbes et al., 2008). Reports on their efficacy in clinical trials for 
inflammatory-associated pathologies, including diabetes, have yet to be published. 
4. Intracellular pathways activated in diabetic kidney 
Intense investigation revealed that numerous inflammatory signaling pathways such as 
phospholipases, protein kinase cascades and transcription factors, are implicated in the 
pathogenesis of DN, from early phase to the progression and final complications. Among 
them, nuclear factor-κB (NF-κB) and janus kinase/signal transducers and activators of 
transcription (JAK/STAT) have a relevant role in the control of immunoinflammatory 
responses in the diabetic kidney. Mechanisms of action and therapeutic opportunities are 
discussed.  
4.1 NF-κB 
The transcription factor NF-κB is induced by various cell stress-associated stimuli including 
growth factors, vasoactive agents, cytokines, and oxidative stress. NF-κB in turn controls the 
regulation of numerous genes activated during inflammation, such as cytokines, 
chemokines, growth factors, cellular ligands, and adhesion molecules (Karin & Greten, 
2005). The activation and nuclear translocation of NF-κB has been demonstrated in diabetic 
kidneys from human and rodents (Mezzano et al., 2004; Liu et al., 2010), and also in 
proximal tubular cells in the urinary sediment of patients with type 2 diabetes (Brosius et al., 
2010). Furthermore, a study integrating gene-expression profiling in human renal biopsies 
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with promoter modeling has identified the specific set of target genes, especially 
chemokines, containing a specific NF-κB promoter module (NFKB_IRFF_01) with a NF-κB 
binding site, that were activated in progressive DN (Schmid et al., 2006). These findings 
emphasize the NF-κB proinflammatory pathway as potentially a major upstream target for 
developing new renoprotective agents in diabetes. There is a raising number of reported 
inhibitors of NF-κB pathway with potential benefits for future therapies in humans. 
Inhibitors can be divided into basic categories according to the step at which NF-κB is 
blocked: 1) upstream of IκB kinase complex; 2) IκB phosphorylation/degradation; 3) nuclear 
translocation; 4) DNA binding; and 5) gene transactivation (Gomez-Guerrero et al., 2011). 
Some of these compounds are in clinical development against various inflammatory 
diseases, but studies in diabetic patients are scarce.  
It has been suggested that the preventive effects of thiazolidinedione, a ligand for 
peroxisome proliferator-activated receptor-Ǆ, are mediated by its antiinflammatory actions, 
including inhibition of NF-κB. Thiazolidinedione caused a reduction in intranuclear NF-κB 
binding activity in type 2 diabetic patients with obesity (Aljada et al., 2001), and ameliorated 
renal injury in experimental diabetic rats through NF-κB inhibition (Ohga et al., 2007). Other 
studies demonstrated that 1,25-dihydroxyvitamin D3 suppresses hyperglycemia-induced 
gene expression by blocking NF-κB activation in mesangial cells (Zhang et al., 2007). Statins 
and fenofibrate also exhibit a downregulating effect on NF-κB pathway in kidneys from 
diabetic rats (Usui et al., 2003; Chen et al., 2008). In the same way, a recent report 
demonstrates that the ameliorative effects of the plant alkaloid berberine on renal 
dysfunction in diabetic rats is associated with its inhibitory function on NF-κB signal 
pathway in the kidney (Liu et al., 2010).  
NF-κB is modulated by upstream enzymes like poly(ADP-ribose) polymerase (PARP). 
Increased PARP activity has been shown to participate in the pathogenesis of diabetic 
complications. Pharmacological inhibition of PARP by two different inhibitors (PJ-34 and 
INO-1001) decreased kidney hypertrophy in type 1 diabetic mice (Drel et al., 2011) and this 
effect was associated with a decrease in NF-κB p50 nuclear translocation (Goh et al., 2008). 
This provides rationale reasons for development and further studies of PARP inhibitors as 
promising approaches to DN. In fact, PARP inhibitors are currently being tested in clinical 
trials for cancer. 
4.2 JAK/STAT 
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is 
an essential intracellular mechanism of cytokines and other stimuli that regulates gene 
expression and cellular activation, proliferation, and differentiation. Members of the 
JAK/STAT pathway have been claimed as new molecular targets of antiinflammatory 
treatment in acute and chronic inflammatory diseases (de Prati et al., 2005; Marrero et al., 
2006), and their activation is involved in the development of the diabetes complications. A 
recent report using a transcriptomic approach documented enhanced expression of a large 
number of JAK/STAT mRNAs and JAK2 protein in glomerular and tubulointerstitial 
regions from patients with both early and progressive DN (Berthier et al., 2009). 
JAK/STAT pathway, especially the JAK2/STAT1/STAT3-dependent axis, contributes to 
high glucose mediated renal cell responses, including enhanced expression of genes 
involved in leukocyte infiltration, cell growth, and fibrosis (Brosius et al., 2010; Brosius, III, 
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2008; Amiri et al., 2002; de Prati et al., 2005; Lu et al., 2009). JAK/STAT also mediates the 
mitogenic and fibrotic actions of cytokines and angiotensin II in the kidney (Marrero et al., 
2006), suggesting that modulation of this pathway may prevent diabetic renal disease. 
Importantly, studies in experimental models of diabetes suggest that the renal protective 
effects of current drugs like captopril, statins and rosiglitazone (Banes et al., 2004; Shi et al., 
2007; Tang et al., 2010b) could be partially attributed to a modulation in JAK/STAT 
phosphorylation. More selective therapies, such as inhibitors of JAK2 and JAK3, and STAT1 
antisense oligonucleotides have been proven to counteract the harmful effects of JAK/STAT 
activation in cultured renal cells and in experimental models of DN (Wang et al., 2002; Shi et 
al., 2007; de Prati et al., 2005). 
The JAK/STAT pathway is controlled through different mechanisms: 1) receptor 
internalization; 2) protein tyrosine phosphatases; 3) protein inhibitors of activated STAT; 
and 4) suppressors of cytokine signaling (SOCS). In particular, SOCS family of intracellular 
proteins has emerged as a potential target to modulate the magnitude and duration of 
JAK/STAT signaling (Yoshimura et al., 2007). SOCS are induced by many pathologic stimuli 
(e.g., cytokines, angiotensin II, chemokines, insulin, immunoglobulins, and lipoproteins) 
thus indicating their involvement in many biologic processes (Ortiz-Munoz et al., 2009; 
Yoshimura et al., 2007; Hernandez-Vargas et al., 2005; Gomez-Guerrero et al., 2004). Our 
group has recently reported an increased expression of SOCS proteins in renal samples from 
patients with progressive DN and diabetic animals (Ortiz-Munoz et al., 2010). In vitro, SOCS 
induction prevented the expression of STAT-dependent genes including adhesion 
molecules, chemokines, and cytokines. In vivo gene therapy with SOCS-expressing 
adenovirus reduced JAK/STAT activation and ameliorated the early renal changes in 
diabetic rats. Further research into inducers of SOCS expression or SOCS mimetics could 
have therapeutic value to prevent or retard the progression of diabetic complications. 
5. Conclusion 
The current knowledge of the cellular and molecular processes involved in the initiation and 
progression of diabetic renal injury continues to expand (Figure 1). Inflammation is now 
recognized as an important player in the pathogenesis of DN, and a number of studies have 
been designed to address whether blockade or modulation of specific inflammatory 
molecules can be beneficial for this disease. Furthermore, the increased understanding of the 
functionality of signal transduction pathways will lead to identification of therapeutic 
targets able to specifically downregulate proinflammatory responses and mediators, 
potentially even harnessing some of the sophisticated regulatory systems designed to 
normally limit the inflammatory response. Nevertheless, because of multiple molecular 
links between inflammation, immune response and diabetes complications, it seems 
unlikely that suppressing one single specific effector molecule could be sufficient to produce 
clinically relevant benefit. Effective treatment and/or prevention of diabetic renal disease 
will therefore require an integrated approach combining multiple strategies to target the 
underlying inflammatory processes. In addition, as diabetes complications require chronic 
treatment, long-term antiinflammatory therapies could potentially have other side effects 
despite improving renal function. Future research will provide answers to these 
uncertainties regarding multiple and long-term interventional therapies based on 
modulation of immunoinflammatory responses. In fact, progress towards therapeutics 
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designed to target specific cytokines, chemokines, growth factors and even transcription 
factors is already well underway. Besides the assessment of pharmacological safety, 
bioavailability, and efficacy in vivo, more clinical studies will further support the potential of 
such strategies to be used in diabetes therapy. 
 
Fig. 1. Immunoinflammatory mechanisms in DN. Elements of the diabetic milieu (high 
glucose, AGEs, angiotensin, and oxidative stress) induce the expression of chemokines and 
adhesion molecules by renal cells, which favours leukocyte infiltration into the kidney. 
Further exposure of kidney macrophages and resident cells to diabetic milieu promotes cell 
activation, with the subsequent release of proinflammatory cytokines (e.g. IL-1, IL-6, TNF-
ǂ), ROS, and profibrotic growth factors (e.g. TGF-ǃ). The initial inflammatory response is 
self-amplified then causing renal injury and cell death.  Furthermore, the fibrotic response 
induces proliferation and extracellular matrix accumulation in mesangial and tubular cells. 
Diabetic renal injury then progresses to glomerulosclerosis and tubulointerstitial fibrosis. 
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